Chemoimmunotherapy Triplet Under Study in Recurrent Ovarian Cancer
Posted: Thursday, November 19, 2020
The novel combination of carboplatin, bevacizumab, and mirvetuximab soravtansine—an antibody-drug conjugate that targets folate receptor alpha—appears to be active in patients with recurrent platinum-sensitive ovarian cancer, according to authors of a study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 833P). David M. O’Malley, MD, of The Ohio State University Comprehensive Cancer Center, and colleagues reported that outcomes were similar to those with the current standard of care, with a manageable adverse-effect profile that offered few surprises.
The results “support further exploration of this combination as an alternative to current treatment regimens for recurrent platinum-sensitive disease,” they stated.
Mirvetuximab soravtansine is composed of an antibody that binds to folate receptor alpha, a cleavable linker, and the maytansinoid DM4 (a tubulin-targeting agent). For the 41 patients in the trial who received full dosing (median age, 63 years; all had one or two lines of previous therapy), the confirmed overall response rate was 81%; the median duration of response was 10.7 months, and the median progression-free survival was 12.0 months. Each participating patient also had folate receptor alpha positivity determined by immunohistochemistry, and their last platinum-free interval was longer than 6 months.
“Nine patients remain on study, with a 17-month median of follow-up,” noted Dr. O’Malley and co-investigators.
Regarding treatment-related adverse effects, they continued, “the most common were consistent with the safety profile of mirvetuximab soravtansine, albeit more frequent.” They included diarrhea, nausea, fatigue, and blurred vision.
Disclosure: The study authors’ disclosure information can be found at oncologypro.esmo.org.
